Using patient-derived cancer models to address health disparities in cancer treatment
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities
University of California, Davis · NCT04410302
This study is trying to create and test cancer models from patients, especially those from minority backgrounds, to see how we can improve cancer treatments for bladder, gastric, liver, and lung cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 21 Years to 100 Years |
| Sex | All |
| Sponsor | University of California, Davis (other) |
| Locations | 2 sites (Orange, California and 1 other locations) |
| Trial ID | NCT04410302 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop and characterize over 200 patient-derived xenografts (PDXs) to investigate cancer health disparities affecting racial and ethnic minorities. The focus is on bladder, gastric, liver, and lung cancers, with a significant portion of PDXs derived from minority patients, particularly Hispanic/Latino Americans, African Americans, and Asian American/Native Hawaiians/Pacific Islanders. The study will utilize these PDXs for preclinical testing of various drug treatments to enhance precision medicine approaches tailored to these populations. Collaborations with the National Cancer Institute and other centers will support the research objectives.
Who should consider this trial
Good fit: Ideal candidates include patients currently receiving treatment for bladder, gastric, liver, or lung cancers who can provide informed consent.
Not a fit: Patients who are not receiving treatment for the specified cancers or who are unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective and personalized cancer treatments for underrepresented racial and ethnic groups.
How similar studies have performed: Other studies have shown promise in using patient-derived xenografts to improve cancer treatment outcomes, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer) * Signed informed consent that will be put on file Exclusion Criteria: * No informed consent obtained * Specimen unacceptable/degraded/etc. * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners * Adults unable to consent
Where this trial is running
Orange, California and 1 other locations
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California, United States (RECRUITING)
- University of California Davis Comprehensive Cancer Center — Sacramento, California, United States (RECRUITING)
Study contacts
- Principal investigator: Luis G Carvajal-Carmona — University of California, Davis
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Malignant Neoplasm